References

1. 1.
   ATKINSON M A，NG D K，WARADY B A，et al.The CKiD study：Overview and summary of findings related to kidney disease progression［J］.Pediatr Nephrol，2021，36（3）：527-538.
2. 2.
   YU S M，NISSAISORAKARN P，HUSAIN I，et al.Proteinuric kidney diseases：A podocyte's slit diaphragm and cytoskeleton approach［J］.Front Med，2018，5：221.
3. 3.
   PERICO L，CONTI S，BENIGNI A，et al.Podocyte-actin dynamics in health and disease［J］.Nat Rev Nephrol，2016，12（11）：692-710.
4. 4.
   DRYER S E，ROSHANRAVAN H，KIM E Y.TRPC channels：Regulation， dysregulation and contributions to chronic kidney disease［J］.Biochim Biophys Acta Mol Basis Dis，2019，1865（6）：1041-1066.
5. 5.
   WIEDER N，GREKA A.Calcium ，TRPC channels ，and regulation of the actin cytoskeleton in podocytes：Towards a future of targeted therapies［J］.Pediatr Nephrol，2016，31（7）：1047-1054.
6. 6.
   ROGG M，MAIER J I，DOTZAUER R，et al.SRGAP1 controls small rho GTPases to regulate podocyte foot process maintenance［J］.J Am Soc Nephrol，2021，32（3）：563-579.
7. 7.
   ROBINS R，BALDWIN C，AOUDJIT L，et al.Rac1 activation in podocytes induces the spectrum of nephrotic syndrome［J］.Kidney Int，2017，92（2）：349-364.
8. 8.
   MAAS R J，DEEGENS J K，SMEETS B，et al.Minimal change disease and idiopathic FSGS：Manifestations of the same disease［J］.Nat Rev Nephrol，2016，12（12）：768-776.
9. 9.
   TIAN D Q，JACOBO S M P，BILLING D，et al.Antagonistic regulation of actin dynamics and cell motility by TRPC5 and TRPC6 channels［J］.Sci Signal，2010，3（145）：ra77.
10. 10.
    LIU W S.Su Wen Xuan Ji Yuan Bing Shi［M］.DING K，annotated.Beijing：China Medical Science Press，2019.
11. 11.
    Huangdi Neijing Suwen［M］.WANG Y Q，annotated.Taiyuan：Shanxi Science and Technology Press， 2019.
12. 12.
    HAN S S，LU Y，WANG Y.A brief discussion on the application of "pungent agents to unblock Xuan" in the treatment of nephrotic proteinuria based on the kidney Xuanfu theory［J］.Shanghai J Tradit Chin Med，2015，49（1）：22-24.
13. 13.
    HAN S S，WANG Y，XU Y Q，et al.Exploration of the essence of "kidney Xuanfu"：The hypothesis of "Xuanfu-podocyte slit diaphragm"［J］.Shanghai J Tradit Chin Med.2013，47（12）：28-30.
14. 14.
    LI R R，LIANG Z Y，ZHANG D F，et al.Application of ephedra triad in the diagnosis and treatment of renal system diseases［J］.Chin J Tradit Chin Med，2021，36（7）：3893-3895.
15. 15.
    LI W W，SHEN P C.Research overview on Mahuang Lianqiao Chixiaodou decoction in the treatment of chronic glomerulonephritis［J］.J Liaoning Univ Tradit Chin Med.2016，18（3）：85-87.
16. 16.
    CHANG K，CHEN J，WANG H J，et al.Efficacy observation of Mahuang Fuzi Xixin decoction in the treatment of nephrotic syndrome with wind-water mutual attack pattern［J］.Chin J Exp Tradit Med Form，2013，19（19）：310-313.
17. 17.
    HAN S S，LU Y，YAO T W，et al.Effects of Yuebi decoction and Gujing formula on glomerular podocyte injury in puromycin aminonucleoside nephropathy rats［J］.J Tradit Chin Med，2018，59（1）：51-55.
18. 18.
    HAN S，YAO T，MA Z H，et al.Exploring the TRPC mechanism of diaphoresis and tonification therapies in the treatment of podocyte injury in focal segmental glomerulosclerosis rats based on Xuanfu theory［J］.Chin J Tradit Chin Med，2018，33（11）：5147-5150.
19. 19.
    SU Z L，LU Y，HAN S S，et al.Effects of Mahuang Fuzi Xixin decoction on blood，urine biochemistry，and renal pathology in a rat model of focal segmental glomerulosclerosis［J］.Jiangsu J Tradit Chin Med，2020，52（12）：81-84.
20. 20.
    ZHOU Y M，KIM C，PABLO J L B，et al.TRPC5 channel inhibition protects podocytes in puromycin-aminonucleoside induced nephrosis models［J］.Front Med （Lausanne），2021，8：721865.
21. 21.
    HUANG J H，HUANG X H，CHEN Z Y，et al.Equivalent dose conversion between animals and between animals and humans in pharmacological experiment［J］.Chin J Clin Pharmacol Therapeut，2004，9（9）：1069-1072.
22. 22.
    ZHANG Y H，ZENG M N，LI B K，et al.Ephedra herb extract ameliorates adriamycin-induced nephrotic syndrome in rats via the CAMKK2/AMPK/mTOR signaling pathway［J］.Chin J Nat Med，2023，21（5）：371-382.
23. 23.
    PABLO J L，GREKA A.Charting a TRP to novel therapeutic destinations for kidney diseases［J］.Trends Pharmacol Sci，2019，40（12）：911-918.
24. 24.
    ZHOU Y M，CASTONGUAY P，SIDHOM E H，et al.A small-molecule inhibitor of TRPC5 ion channels suppresses progressive kidney disease in animal models［J］.Science，2017，358（6368）：1332-1336.
25. 25.
    SCHALDECKER T，KIM S，TARABANIS C，et al.Inhibition of the TRPC5 ion channel protects the kidney filter［J］.J Clin Invest，2013，123（12）：5298-5309.
26. 26.
    WEN Y M，LI P.Research progress on pathological mechanisms of puromycin aminonucleoside nephropathy rat models［J］.Chin J Integr Tradit West Nephrol，2013，14（2）：172-174.
27. 27.
    ALBERT A P，SALEH S N，LARGE W A.Identification of canonical transient receptor potential （TRPC） channel proteins in native vascular smooth muscle cells［J］.Curr Med Chem，2009，16（9）：1158-1165.
28. 28.
    YE Y，GAO M R，FENG L，et al.Isoliquiritigenin-induced vasodilation by activating large-conductance Ca²⁺-activated K⁺ channels in mouse mesenteric arteries［J］.Clin Exp Pharmacol Physiol，2019，46（11）：1044-1052.
29. 29.
    QI J，CUI J G，MI B B，et al.Isoliquiritigenin inhibits atherosclerosis by blocking TRPC5 channel expression［J］.Cardiovasc Ther，2020，2020：1926249.
30. 30.
    KIM H J，CHA B Y，PARK I S，et al.Dehydroglyasperin C，a component of liquorice，attenuates proliferation and migration induced by platelet-derived growth factor in human arterial smooth muscle cells［J］.Br J Nutr，2013，110（3）：391-400.
31. 31.
    SALEEM M A，O'HARE M J，REISER J，et al.A conditionally immortalized human podocyte cell line demonstrating nephrin and podocin expression［J］.J Am Soc Nephrol，2002，13（3）：630-638.
32. 32.
    MUNDEL P，REISER J，BORJA A Z M，et al.Rearrangements of the cytoskeleton and cell contacts induce process formation during differentiation of conditionally immortalized mouse podocyte cell lines［J］.Exp Cell Res，1997，236（1）：248-258.
33. 33.
    CHEN C W，FENG J，HU J J，et al.Primary culture and characterization of dual fluorescent-labeled murine renal podocytes［J］.J Wuhan Univ：Med Ed，2022，43（6）：902-907.
34. 34.
    GU J，ZHANG C J，JIA L，et al.Primary culture of rat podocytes and specific expression of Nephrin［J］.Guangdong Med J，2017，38（6）：825-829.
35. 35.
    SCHELL C，ROGG M，SUHM M，et al.The FERM protein EPB41L5 regulates actomyosin contractility and focal adhesion formation to maintain the kidney filtration barrier［J］.Proc Natl Acad Sci USA，2017，114（23）：E4621-E4630.